As previously reported, Jefferies upgraded Rigel Pharmaceuticals (RIGL) to Buy from Hold with a price target of $42, up from $23, after Q3 product sales beat Street expectations and the company raised total 2025 net product sales guidance to $225M-$230M from $210M-$220M. The firm cites strong commercial execution, positive cash flow and room for potential business development for its upgrade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals upgraded to Buy from Hold at Jefferies
- Midday Fly By: Broader market bought on dip after tech selloff
- Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald
- Rigel Pharmaceuticals Reports Strong Q3 2025 Results
- Rigel Pharmaceuticals reports Q3 EPS $1.46, consensus 94c